Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.
Nancy L. Lewis, MD
Advertisement
Articles by Nancy L. Lewis, MD
Advertisement
Latest Updated Articles
Dr. Nancy Lewis Discusses the Regorafenib CORRECT TrialOctober 18th 2012
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/12
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Five Under 5: Top Oncology Videos for the Week of 7/12
4
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
5